TGR5 Modulators Targeting Bile Acid Signaling for Metabolic Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current strategies for treating obesity and diabetes, particularly in the context of metabolic syndrome, are inadequate as they primarily manage symptoms rather than addressing the root causes, and there is a need for more effective agents that can target the underlying mechanisms of these conditions.

Innovation Solution

Development of specific heterocyclic compounds that act as TGR5 modulators, which can be administered to modulate TGR5 activity and treat TGR5-mediated diseases such as obesity, diabetes, and metabolic syndrome by targeting the BA-TGR5-cAMP-D2 signaling pathway.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatment strategies for obesity and diabetes are used, then symptom management is achieved, but root causes are not addressed

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to address root causes

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent introduces TGR5 modulators as intermediary compounds that mediate between bile acid signaling and metabolic regulation. These compounds act as selective mediators targeting the TGR5 receptor to activate downstream cAMP signaling pathways, thereby addressing root causes of metabolic disorders rather than merely managing symptoms. The modulators serve as a bridge between endogenous bile acids and therapeutic effect, enabling precise control over metabolic pathways.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If TGR5 modulators are developed to target the BA-TGR5-cAMP-D2 signaling pathway, then treatment of metabolic diseases is improved, but treatment complexity increases

Engineering Contradiction:

Improvedisease treatment efficacyVSAvoidtreatment mechanism complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the critical TGR5 receptor and its downstream signaling components (cAMP, D2 enzyme) as the specific therapeutic target. By focusing on this extracted signaling pathway rather than attempting to modify the entire metabolic system, the invention simplifies the treatment approach while maintaining high efficacy. The modulators are designed to specifically interact with TGR5, separating the essential therapeutic mechanism from complex metabolic networks.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs parameter changes by modifying the chemical structure of TGR5 modulators through various substituents (R1-R7 groups) to optimize binding affinity and selectivity. By systematically varying molecular parameters such as substituent types, positions, and configurations, the invention fine-tunes the interaction between modulators and TGR5, achieving high efficacy while managing structural complexity through rational design.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These compounds effectively treat a wide range of metabolic, cardiovascular, and inflammatory diseases by modulating TGR5 activity, improving energy homeostasis and reducing the risk of associated conditions like coronary artery disease and stroke.

Implementation Method 1

TGR5 is a seven transmembrane Gs-coupled GPCR and stimulation by ligand binding causes activation of adenylyl cyclase which leads to the elevation of intracellular cAMP and subsequent activation of downstream signaling pathways

Methodology Applied

Scientific EffectG-protein coupled receptor signaling: